SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-010217
Filing Date
2018-02-14
Accepted
2018-02-14 21:23:48
Documents
2
Period of Report
2018-02-13

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1560
2 POA DOCUMENT poa.txt EX-24.3_769124 3111
  Complete submission text file 0001209191-18-010217.txt   6353
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Issuer) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences

Mailing Address 385 OYSTER POINT BLVD., SUITE 9A SOUTH SAN FRANCISCO CA 94080
Business Address
Tucker Sean (Reporting) CIK: 0001652204 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35285 | Film No.: 18615932